YMYiyi Ma

Yiyi Ma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yiyi Ma has a total of 718 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Fibronectin mediates APOE4-driven blood–brain barrier dysfunction in Alzheimer’s disease

    by Prabesh Bhattarai, Elanur Yilmaz, Elif Öykü Cakir, Huseyin Tayran, Imdadul Haq, Dylan Murphy, Jonah Nadelmann Keller, Quentin Le Grand, Jacqueline O. Eschbach, Hilal Celikkaya, et al.

    Blood–brain barrier (BBB) dysfunction is an early feature of Alzheimer’s disease (AD) and is particularly pronounced in individuals carrying the APOE ε4 allele, but the mechanisms linking APOE ε4 to BBB failure remain unclear. Here we show that astrocyte-derived fibronectin (FN1) is a key mediator of apolipoprotein E4 (APOE4)-driven BBB dysfunction in AD. Using postmortem human brain tissue, human three-dimensional vascular models and in vivo models, we demonstrate that APOE4, amyloid-β42 and inflammatory signals induce astrocytic FN1 upregulation and excessive perivascular deposition. Fibronectin accumulation is sufficient to cause BBB leakage and disrupt VEGF/HB-EGF/IGF-1 signaling through integrin-mediated focal adhesion kinase activity. Reducing fibronectin or restoring growth factor signaling rescues BBB function in vitro and in vivo. Together, evidence from experimental models, human brain tissue and clinical datasets identifies fibronectin as a proximal mediator of APOE4-driven gliovascular dysfunction and highlights FN1 as a potential therapeutic target for vascular and BBB dysfunction in AD.


  • Open Access

    Single-nucleus multiomics in brains from Hispanic individuals reveal APOE-ε4 -driven disruption of focal adhesion signaling in the presence of cerebrovascular pathology

    by Elanur Yilmaz, Kevin W. Chen, Elif Öykü Cakir, Prabesh Bhattarai, Minghua Liu, Benjamin L. Ciener, Min Qiao, Rafael Lantigua, Martin Medrano, Diones Rivera, et al.

    The apolipoprotein E ε4 allele ( APOE-ε4 ) is the strongest genetic risk factor for late-onset Alzheimer’s disease (AD), yet its molecular impact on cerebrovascular biology remains inconclusive, particularly in underrepresented populations with elevated vascular burden. Individuals from Hispanic ancestry experience disproportionately high rates of cerebrovascular pathology, offering a unique opportunity to investigate the mechanisms of cerebrovascular pathology in AD. Here, we performed single-nucleus RNA sequencing (snSeq) on 413,175 nuclei from 52 postmortem Hispanic brains to determine APOE-ε4 -associated cell type specific transcriptomic changes in a population with elevated cerebrovascular risk. We identified a conserved molecular signature marked by dysregulated extracellular matrix deposition and focal adhesion signaling in astrocytes. These findings were replicated in the non-Hispanic ROSMAP cohort (n = 424) snSeq. Findings were validated in isogenic human iPSC-derived astrocytes, humanized APOE targeted replacement mouse brains, and post-mortem human brains at protein and chromatin accessibility level. Our data suggest that APOE-ε4 astrocytes adopt a hyper-adhesive, mechanically rigid phenotype that may exacerbate cerebrovascular pathology.


  • Open Access

    A factor-based analysis of individual human microglia uncovers regulators of an Alzheimer-related transcriptional signature

    by Victoria S. Marshe, John F. Tuddenham, Kevin Chen, Rebecca Chiu, Verena C. Haage, Yiyi Ma, Annie J. Lee, Neil A. Shneider, Julian P. Agin-Liebes, Roy N. Alcalay, et al.

    Human microglial heterogeneity is only beginning to be appreciated at the molecular level. Here, we present a large, single-cell atlas of expression signatures from 441,088 live microglia broadly sampled across a diverse set of brain regions and neurodegenerative and neuroinflammatory diseases obtained from 161 donors sampled at autopsy or during a neurosurgical procedure. Using single-cell hierarchical Poisson factorization (scHPF), we derived a 23-factor model for continuous gene expression signatures across microglia which capture specific biological processes (e.g., metabolism, phagocytosis, antigen presentation, inflammatory signaling, disease-associated states). Using external datasets, we evaluated the aspects of microglial phenotypes that are encapsulated in various in vitro and in vivo microglia models and identified and replicated the role of two factors in human postmortem tissue of Alzheimer’s disease (AD). Further, we derived a complex network of transcriptional regulators for all factors, including regulators of an AD-related factor enriched for the mouse disease-associated microglia 2 (DAM2) signature: ARID5B , CEBPA , MITF , and PPARG . We replicated the role of these four regulators in the AD-related factor and then designed a multiplexed MERFISH panel to assess our microglial factors using spatial transcriptomics. We find that, unlike cells with high expression of the interferon-response factor, cells with high expression of the AD DAM2-like factor are widely distributed in neocortical tissue. We thus propose a novel analytic framework that provides a taxonomic approach for microglia that is more biologically interpretable and use it to uncover new therapeutic targets for AD.


  • Open Access

    Cataloging the role of brain cell types on suppressing the effect of APOE ε4 on Alzheimer’s disease risk

    by Yiyi Ma, Kevin W Chen, Masashi Fujita, Lei Yu, Vilas Menon, Julie A Schneider, David A. A Bennett, Philip L De Jager

    Background: We have previously developed a research pipeline to identify potential suppressors of APOE ε4 risk on Alzheimer’s disease (AD), and we have successfully identified an epigenomic factor which may act as ε4 suppressor. However, it is unknown which cell type is more important to contain this ε4 suppressor on the transcriptome level.Method: We included single‐nucleus RNA sequencing (snRNAseq) data of the postmortem human brains from 424 subjects of the Religious Orders Study or the Rush Memory and Aging Project (ROSMAP). Based on this snRNAseq data, we have derived the estimate of the percentage and transcriptomic profiles of different types of brain cells including excitatory neurons, inhibitory neurons, endothelial cells, pericytes, oligodendrocytes, astrocytes, and microglia. Besides the main cell types, we further derived the estimates on the cell subtype level. With the generalized linear regression model, the final prioritized cell types and genes should fulfill two criteria: (1) be associated with AD pathologies (pTAU and neuritic plaque) in all subjects; and (2) reduce the effect of ε4 on AD susceptibility.Result: Based on the transcriptome‐wide association study (TWAS) of the main brain cells, almost all the brain cell types contain at least one genome‐wide significant (P≤6.5×10−6) gene which can act as the APOE ε4 suppressor on AD risk. However, the subtype cellular analysis suggested that neuronal subtypes are more important than the other cell types because almost all the subtypes of the excitatory neuronal cells (15 out of 16) contain the genome‐wide significant ε4 suppressor while this percentage for microglia is only 25% (4 out of 16). The pathway analysis suggested that the top 179 genes expressed in the neuronal cells were involved in the trans‐synaptic signaling by trans‐synaptic complex and synapse assembly.Conclusion: On the transcription level, APOE ε4 suppressor effects are present across a variety of different brain cell types but enriched in neurons where synapse pathways appear to play a predominant role in suppressing the effect of APOE ε4.

  • Top Cited Papers
    Open Access

    New insights into the genetic etiology of Alzheimer’s disease and related dementias

    by Céline Bellenguez, Fahri Küçükali, Iris E. Jansen, Luca Kleineidam, Sonia Moreno-Grau, Najaf Amin, Adam C. Naj, Rafael Campos-Martin, Benjamin Grenier-Boley, Victor Andrade, et al.

    Characterization of the genetic landscape of Alzheimer’s disease (AD) and related dementias (ADD) provides a unique opportunity for a better understanding of the associated pathophysiological processes. We performed a two-stage genome-wide association study totaling 111,326 clinically diagnosed/‘proxy’ AD cases and 677,663 controls. We found 75 risk loci, of which 42 were new at the time of analysis. Pathway enrichment analyses confirmed the involvement of amyloid/tau pathways and highlighted microglia implication. Gene prioritization in the new loci identified 31 genes that were suggestive of new genetically associated processes, including the tumor necrosis factor alpha pathway through the linear ubiquitin chain assembly complex. We also built a new genetic risk score associated with the risk of future AD/dementia or progression from mild cognitive impairment to AD/dementia. The improvement in prediction led to a 1.6- to 1.9-fold increase in AD risk from the lowest to the highest decile, in addition to effects of age and the APOE ε4 allele.


  • Open Access

    Human peripheral monocytes capture elements of the state of microglial activation in the brain

    by Daniel Felsky, Hans-Ulrich Klein, Vilas Menon, Yiyi Ma, Yanling Wang, Milos Milic, Peter Zhukovsky, Julie Schneider, David Bennett, Philip De Jager

    Despite a growing focus on neuroimmune mechanisms of Alzheimer’s disease (AD), the role of peripheral monocytes remains largely unknown. Circulating monocytes communicate with the brain’s resident myeloid cells, microglia, via chemical signaling and can directly infiltrate the brain parenchyma.1 Thus, molecular signatures of monocytes may serve as indicators of neuropathological events unfolding in the CNS.2–5 However, no studies have yet directly tested the association of monocyte gene expression on longitudinal cognitive decline or postmortem neuropathology and brain gene expression in aging. Here we present a resource of RNA sequencing of purified CD14+ human monocytes - including an eQTL map - from over 200 elderly individuals, most with accompanying bulk brain RNA sequencing profiles, longitudinal cognitive assessments, and detailed postmortem neuropathological examinations. We tested the direct correlation of gene expression between monocytes and bulk brain tissue, finding very few significant signals driven largely by genetic variation. However, we did identify sets of monocyte-expressed genes that were highly predictive of postmortem microglial activation, diffuse amyloid plaque deposition, and cerebrovascular disease. Our findings prioritize potential blood-based molecular biomarkers for AD; they also reveal the previously unknown architecture of shared gene expression between the CNS and peripheral immune system in aging.


  • Open Access

    Proximal and distal effects of genetic susceptibility to multiple sclerosis on the T cell epigenome

    by Tina Roostaei, Hans-Ulrich Klein, Yiyi Ma, Daniel Felsky, Pia Kivisäkk, Sarah M. Connor, Alexandra Kroshilina, Christina Yung, Belinda J. Kaskow, Xiaorong Shao, et al.

    Identifying the effects of genetic variation on the epigenome in disease-relevant cell types can help advance our understanding of the first molecular contributions of genetic susceptibility to disease onset. Here, we establish a genome-wide map of DNA methylation quantitative trait loci in CD4+ T-cells isolated from multiple sclerosis patients. Utilizing this map in a colocalization analysis, we identify 19 loci where the same haplotype drives both multiple sclerosis susceptibility and local DNA methylation. We also identify two distant methylation effects of multiple sclerosis susceptibility loci: a chromosome 16 locus affects PRDM8 methylation (a chromosome 4 region not previously associated with multiple sclerosis), and the aggregate effect of multiple sclerosis-associated variants in the major histocompatibility complex influences DNA methylation near PRKCA (chromosome 17). Overall, we present a new resource for a key cell type in inflammatory disease research and uncover new gene targets for the study of predisposition to multiple sclerosis.


  • Open Access

    Neuroticism alters the transcriptome of the frontal cortex to contribute to the cognitive decline and onset of Alzheimer’s disease

    by Céline H. De Jager, Charles C. White, David A. Bennett, Yiyi Ma

    Accumulating evidence has suggested that the molecular transcriptional mechanism contributes to Alzheimer’s disease (AD) and its endophenotypes of cognitive decline and neuropathological traits, β-amyloid (Aβ) and phosphorylated tangles (TAU). However, it is unknown what is the impact of the AD risk factors, personality characteristics assessed by the NEO Five-Factor Inventory, on the human brain’s transcriptome. Using postmortem human brain samples from 466 subjects, we found that neuroticism has a significant overall impact on the brain transcriptome (omnibusP = 0.005) but not the other four personality characteristics. Focused on those cognitive decline related gene co-expressed modules, neuroticism has nominally significant associations (P < 0.05) with four neuronal modules, which are more related to PHFtau than Aβ across all eight brain regions. Furthermore, the effect of neuroticism on cognitive decline and AD might be mediated through the expression of module 7 and TAU pathology (P = 0.008). To conclude, neuroticism has a broad impact on the transcriptome of human brains, and its effect on cognitive decline and AD may be mediated through gene transcription programs related to TAU pathology.


  • Epigenomic features related to microglia are associated with attenuated effect of APOE ε4 on Alzheimer’s disease risk in humans

    by Yiyi Ma, Lei Yu, Marta Olah, Rebecca G. Smith, Ehsan Pishva, Vilas Menon, Katie Lunnon, David A. Bennett, Hans‐Ulrich Klein, Philip L. De Jager

    Background: Not all APOE ε4 carriers who survive to advanced age develop Alzheimer’s disease (AD); factors attenuating the ε4 risk on AD may exist.Method: Guided by the top ε4‐attenuating signals from methylome‐wide association analyses (N = 572, ε4+ and ε4‐) of neurofibrillary tangles and neuritic plaques, we conducted a meta‐analysis for pathological AD within the ε4+ subgroups (N = 235) across four independent collections of brains. Cortical RNA‐seq and microglial morphology measurements were used in functional analyses.Result: Three out of the four significant CpG sites were captured by one principle component (PC1), which interacts with ε4 on AD, and is associated with expressions of innate immune genes and activated microglia. In ε4 carriers, reduction in each unit of PC1 attenuated the odds of AD by 59% (OR = 2.41, 95%CI = [1.64,3.52], P = 7.40 × 10−6).Conclusion: An epigenomic factor associated with a reduced proportion of activated microglia appears to attenuate the risk of ε4 on AD.


  • Alzheimer's disease GWAS weighted by multi‐omics and endophenotypes identifies novel risk loci

    by Yiyi Ma, Badri N. Vardarajan, Charge Adsp Fus, David A. Bennett, Myriam Fornage, Sudha Seshadri, Anita L. Destefano, Philip L. De Jager

    Background: We have increasing information on the role of certain genetic variants in a wide variety of molecular traits and endophenotypes of Alzheimer’s disease (AD), but their impacts on the prioritization of AD risk gene are unknown.Method: Based on the summary statistics of the genome‐wide association study (GWAS) of AD published by the International Genomics of Alzheimer’s Project (IGAP) consortium (Kunkle et al., 2019), we have weighted each SNP by their associations with traits of eQTL (RNA expression), mQTL (DNA methylation), haQTL (histone acetylation), brain phosphorylated tangles (TAU), β‐amyloid protein (Aβ), and cognitive decline derived from the ROS‐MAP samples of postmortem dorsal‐lateral prefrontal cortex of AMP‐AD. Then, we collapsed all of the weighted SNPs found in each gene using the SKATO test, based on the 1000 reference genome.Result: 38∼43% of genes (n = 12,899) have an increase in their statistical significance level after incorporating the weights of their genetic effects on omic molecular traits and AD endophenotypes. A subset of these gene‐level assessments reach the trait‐specific Bonferroni corrected genome‐wide significance threshold (P < 0.05/number of genes for each trait). The burden of TAU pathology has the strongest effect with RASGRF2, FCF1, ZCWPW1, C6orf10, VAC14, ADGRF2, ACP2, DDB2, and CR1L being prioritized. Similarly, we have results prioritized by weighting by (1) Amyloid β: FCF1, NRXN1, PLCB1, and DLG2; (2) cognitive decline: AKAP13, CR1L, KIAA1671, and CR2; and (3) eQTL: TRIT1, RAPSN, and C6orf10. The latter also emerges from the haQTL analysis, and no results emerge from the mQTL analysis.Conclusion: Weighting by omic molecular traits and endophenotypes leading to AD is able to prioritize additional genes that could contribute to AD susceptibility. Functional validation is ongoing.